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Abstract 
Growth factors have represented an essential issue of interest for the researchers and clinicians in orthopedics and trauma 
over the last 40 years. In the last 10 to 15 years, the advances registered in this field have permitted the identification of the most 
active cellular and humoral factors as well as the improvement of their use in the orthopedic and trauma surgery. Their domain of 
application has been continuously enlarged and the results have been visible from the beginning. The authors present their 
appreciation on the actual state of this subject as well as their experience with results and related conclusions. 
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Introduction 
For several decades, orthopedic surgeons have 
been searching feverishly for a new approach in the 
therapy of the pseudarthrosis, osteochondronecrosis, 
essential osteolysis or, generally speaking, to treat various 
diseases that require bone reconstruction. 
Eclectic, even since the last century, the utilization 
of the bone marrow, amnios, placenta, bladder mucosa of 
the human fetus has demonstrated the osteogenic 
stimulative effect of these anatomical formations that are 
of mesenchymal provenience. Hematologists have used 
the bone medullar implants in different blood diseases, 
with the intention of normal regeneration of blood 
figurative elements from the original sanguine cell  (“the 
root” where the general terminology “STEM” cell is coming 
from), and the method has been extended. 
The metaplasic potential of the primordial 
mesenchyme is not contested, but taking into 
consideration the bone case (braditrophyc tissue par 
excellence), besides bone grafts harvested from certain 
areas (postero-superior iliac crest, ribs etc.), the 
experience with favorable follow-up, there are some other 
natural humoral or induced factors added, that are in favor 
of developing osteoprogenitor factors activity of these 
grafts.  
Without mentioning the things already known, we 
will present a few historical facts belonging to this new 
reconstructive therapeutical thinking, in orthopedics and 
trauma. 
The facts and conclusions we already have, led us 
to more profound specific studies, in order to identify all 
stimulative factors of growth and osteogenesis that could 
be used by the specialists as one of their therapeutic 
methods. 
General data 
Basically, bone-stimulative therapy with growth 
factors is based today on a few precise findings 
experimentally confirmed: 
1.  The common origin (STEM = root) of the cells 
with great regeneration potential (red bone 
marrow, granulation conjunctive tissue – young 
and non-differentiated, vascular endothelium 
etc.) is mesenchymal. 
2.  Great metaplasic and progenitor potential of 
these cells, with clear trophic characteristics 
and embryonic origin, which are especially 
present in the braditrophic structures (as the 
bone is). 
3.  The growing enzymatic equipment (TGF), the 
morphogenetic proteins (BMP) and tissular 
cytokines released in certain conditions are 
incontestable agents in the stimulation of the 
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regeneration and specific cellular growth with 
stimulative effect on the functions of these cells. 
4.  The origin of the growth factors (5 subtypes, 
among which TGF is the most powerful) is 
variable enough: 
−  Platelets. 
−  Osteocytes-osteoblasts. 
−  Bone matrix (IGF II). 
−  Some fibroblasts (especially medullary 
endosteal). 
−  Medullocytes. The role of the bone marrow in 
osteogenesis has been underlined since 1877 
(Olier), 1881 (Kolliker), 1928 (Sandison) and 
1934 (McGrow). Nade, Burwell (1977) and 
Salama (1983) have developed the researches 
by applying the observations to the clinical 
backgrounds (Ghergulescu, Diaconescu and 
Zaharia in our country). 
−  Some components of the deep layers of the 
periosteum (?) 
−  Humoral products derived from clot lysis 
phases (?) 
Experimentally, it has been demonstrated that 
mammals have molecular signals and reactive cells that 
initiate osteogenesis in their bones. These cells have two 
precursor cellular lines: one determinant line and one 
inductive line. The cells derived from the last one are 
responsible for the bone formation, through induction, by 
demineralized matrix (extracellular) and morphogenetic 
bone proteins. Recently, the BMP genes have been 
cloned and the modality of action of the recombinant 
proteins has been clarified:  pleiotropic initiators of the 
precursor inductive osteogenic cells. 
Osteogenesis is governed by the BMP in all three 
stages: 
1.  chemotaxis 
2.  mitosis 
3.  differentiation 
Recently, the BMP receptors have been identified 
and cloned, they are of two types (type I and II), divided 
into membranes – limit seryn / threonine “proteinkinase”. 
With the help of these receptors “the binding” of two 
extracellular matrices is achieved and thus, “continuing 
and rhythmic differentiation osteoblast – osteocyte” is 
determined. 
From the things shortly exposed above it is easy to 
understand why the researchers are so concerned about 
using BMP in clinical cases. 
Jensen, Overgaard, Lind (1998) have highlighted 
the importance of the osteogenic protein OP-1 (BMP-7) in 
osteoinduction, this protein having a determinant role in 
the bone graft fixation at the site of the receptor host. This 
protein action manifests on the collagen fibers, on the 
hydroxyapatite and on the matrix of the minerals fixation 
(stimulative role through osteoinductive effect that has as 
a result the “capturing” tendency of these matrixes, of the 
stem cells and other osteoprogenitor factors). 
These few conclusions represent only the essence 
of some long time research in the  domain; right now we 
are in the phase when the eclectic approach is leading us 
towards certain directions (let's remember the 60-70 years 
when preparates of the placenta, such as the amnios, 
fetus bladder mucosa, even staphylococcal anatoxin, were 
very well used in the local treatment of pseudarthrosis). 
Bone reconstruction mechanisms 
The basic biological processes that lead to bone 
reconstruction, a domain we cannot act by stimulating 
them, are osteoconduction and osteoinduction. 
 
Osteoconduction is represented by the 
formation and the development of the conjunctive-vascular 
buds and those of the adjacent structures (of 
mesenchymal origin) that grow and penetrate the tissues 
and are repopulated with the help of local osteoprogenitor 
cells or with cells derived from autologous cultures. The 
process of participation of the osteoprogenitor fibroblasts 
from the homologous cultures to osteoconduction, into 
bone grafts sites is still being studied. Certainly, 
osteoconduction is efficient only if both osteoinductive 
substances and osteogenic cyto-humoral elements are 
present in the same region. Among the allogeneic 
materials (substances) that were credited with such 
properties only the Calcium sulfate, bio-active glass and 
some polymers (still in experimental phase) have given 
encouraging results, the others (hydroxyapatite, 
phosphates, aluminum derivates) have offered 
contradictory results (clinical and experimental). These 
materials have an important helping role in the treatment 
of large bone defects or of big floating pseudarthrosis, in 
association with autologous biological materials 
(spongious auto-grafts, preserved depopulated matrix, 
medullary aspirate) that have an osteoinductive role. 
 
Osteoinduction represents the totality of the 
humoral factors, physical, cellular (primordial) and of 
chemotaxis (probable), which by their local and general 
action they influence: 
1.  The production and complex adjusting 
(hormonal, biochemical, trophical) of the 
enzymatic osteostimulatory factors. 
2.  “The calling” in and at the site, of the 
mesenchymal cellular elements with 
osteoformative metaplasic potential (cells with 
“adult” STEM cell characteristics), 
simultaneously with the synthesis and the 
increase of the local concentration of some 
enzymatic factors (growth factors) with 
inductive role. 
We remembered the most well known factors 
(TGF-β1-2, BMP5, the complex BMC-BMP, BBC-BMP 
etc.) besides the physical procedures (electrical and 
electromagnetic, ultrasounds etc.), but the research 
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continues for the identification of certain substances that 
appear during bone remodeling and reconstruction 
process, with an obvious action (we remember our 
research in osteoinduction activation after the lysis phase 
of the clot). 
The theories of the osteoconduction can be 
sketched, as evolution in time as: 
1.  Induction through BMP (Wrist, 1967). 
2.  Metaplasia of the yellow bone marrow into 
osteoprogenitor tissue when it is transferred 
into vascular zone. (Tavasili, 1970). 
3.  Theory of the double origin of the bone callus 
(Dan,1973). 
4.  Induction by BMP and other humoral factors 
(Linholm, Wrist, 1980-1987). 
We have to take into consideration the 
osteoinductive mechanisms in the osteogenesis 
stimulation and structural formation, in function of the 
mechanical tasks from a bone modeling or remodeling 
area, in order to influence them, eventually. 
The osteoinduction, a notion that includes local and 
general mechanisms with biochemical characteristics, 
enzymatic, physical and of tactism, determines: 
1. The selection of the cells of mesenchymal origin 
with multiple metaplasic potential (STEM), but 
which can be stimulated into osteoformative 
direction. 
2. The production and contribution of the growing 
humoral factors (osteoprogenitors), from the 
humors of the body, own bone matrix, local 
enzymatic reactions (clot lysis), the cells and 
sanguine protein factors, etc. 
3. Local neuro-vasculo-humoral adjusting through 
some tissular receptors (hypothetical) of the 
complex process of osteolysis-bone 
reconstruction (osteoclast-osteoblast activity). 
4. The changes of type A collagen, following the 
conduction, in the early stages, of the 
proteoglican synthesis (agrecan – organizer of 
the extracellular matrix) by several factors, in 
such way that the new-formed bone suffered 
variations into its composition until its definitive 
structure was complete (osteoinduction initiation 
would be started by an osteogenic protein – OP1 
– after Jensen, Overgaard, Lind and Wrist). 
To the three initial classic groups of growth factors 
(TGF-b) represented by the BMP group (11-12 factors), 
TGF-b group (5 factors) and the group of the inhibins (3 
factors), we have added (after clinical observations) and 
researches another 4th group, of local tissular stimulins 
(cytokines) which appeared from the clot lysis and from 
local destructions of the tissue. 
Regarding the fresh spongious bone graft that 
contains mesenchymal STEM cells type, which present a 
combination of the osteoinduction process with another 
plastic complex process, osteoconduction, during its 
integration, it assures a balanced three-dimensional 
remodeling of the new bone on the offered ,,skeleton”. 
Osteoblast activity is situated in the center of the 
osteoconduction mechanisms. Moreover, it is implied in all 
the phases of this mechanism such as “the quiet period”, 
“the activation period”, “resorption”, “the reversion period” 
and “the new bone formation period”. 
The growth (osteoprogenitor) factors 
diversity 
Cellular factors: 
-  STEM type cells – medullocytes, undifferentiated 
fibroblasts. 
-  PDGF, resulted from platelets. 
-  Osteoprotegerin from osteoblasts- with action on 
the RANK-receptors (bone resorption inhibition). 
-  Sinoviocytes that in certain conditions modify 
their metabolism and become cells with 
osteoclast characteristics. 
-  Substances from the medium culture that are 
inducing the increased activity of the 
phosphatases. 
The main source of stem cells is the embryo 
(embryonic cells), with multiple potential and which can be 
preserved for a long time. In order to obtain cells with 
osteoprogenitory capacity from the adult, these must be 
harvested from the foam desmale bone (iliac crest, rib, 
vertebral body), which has the largest medulocytes 
concentration and has the ability to form fibroblasts with 
osteoformative potential (CFV -F).  
 
Humoral factors: 
-  TGF (5-6 subtypes). 
-  BMP. 
-  Tissular cytokines. 
-  Prostaglandins. 
-  Insulin Like Growth Factor (IGF). 
-  Fibroblastic Growth Factor (FGF). 
-  VGF. 
-  Epidermal Growth Factor (EGF). 
-  Interleukins (I1-1, I1-2, I1-10). 
-  Different forms of eritropoetins. 
-  Substances derived from the sanguine clot lysis. 
 
Other factors: 
-  Factors of the bone matrix: 
•  desmal bone matrix – with osteoinductive 
action; 
•  pleiotrophins from the bone matrix, 
-  Chemical factors – dexamethasone - in vivo 
-  Metals: Zn, Ti. 
-  Electrical factors – galvanic fields. 
Changes that reveal the fact that bone remodeling is 
happening in small morfo-bio-chemical packages, 
coherent, rhythmic and harmoniously coordinated can be 
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observed at the level of the general skeletal homeostasis, 
during the bone growth stimulation process (Parfitt, 1988). 
Different enzymes, cytokines, humoral factors with 
multiple potential (prostaglandins, calcitonin) interfere in 
different osteogenesis phases in the bone remodeling 
sites, graft integration, osteolysis etc., and the processes 
are unfurled at the level of the so called “bone remodeling 
units”, in time units determined by the local resorption-
reconstruction process (bone turn-over rate), irrespective 
of the bone remodeling modality. (woven-bone or “direct” 
remodeling). 
It is known that, in certain conditions, the cells from 
hematopoetic stromal medium selectively interact with 
unspecific STEM cells and influence their development 
(experiments on mouse), even if these are not coming 
from hematopoetic STEM cells, this demonstrating the 
very great plastic potential of the STEM cells. 
The actions of some factors like the following are 
still being researched today: 
-  ,,Alpha” (TGF) Growth factor  from tumoral cells 
culture; 
-  Tumoral growth factors, would be of interest if 
they could be controlled from the quality and 
quantity point of view; 
-  Transforming growth factor β (TGF-β); 
-  Insulin-like growth factor (IGF); 
-  Fibroblast and epidermal growth factors; 
-  Some of the interleukins; 
-  Eritropoetin; 
-  Piezoelectricity activity and “narrowing” the 
potentials (streanning) of the fluids to flow into 
the bone; 
-  Some metals (titan, zirconium); 
-  ,,Anchoring” cells; 
-  Some of the proteases (metaloproteases); 
-  Depopulated bone matrices, degreased, dried 
and sprayed, with an obvious osteoprogenitor 
role in the case of their utilization as autologous 
graft or added in the medium culture of the 
autologous osteoformators fibroblasts; 
-  The interferon; 
-  Some retroviruses; 
-  Some markers or substances appeared into the 
osteoblasts’ medium cultures (sialoproteins, 
osteoprotegerin, etc.); 
-  Sinoviocytes (as mesenchymal cells with 
different potential); 
-  Some substances (dexamethasone, calcium 
preparations, intermediar products of Vitamin D3 
metabolism) that positively influence the 
osteoblasts’ cultures. 
Practical utilization of the osteoprogenitor 
factors 
The history of the use and the research of the 
STEM-type preparations is unfurled on a long period of 
time (about 35-40 years), from simple clinical and 
statistical observations reaching today, in the phase of 
synthesizing specific proteins and enhancing cell cultures. 
We can affirm that the bases of the systematic study 
of the STEM cells’ role into bone consolidation belong to 
Maureen Owen (1976, 1988, 1995), but earlier to Wrist 
(1965 – the first who mentions the existence of BMP into 
osteoblast). Raisz, Rodan, Creenshaw, Frost, Yamaguchi, 
Ripamonti, V.Ranga etc. have contributed to this study. 
Recently (1977), in our country, N. Ghergulescu and 
S. Diaconescu, in Republic Moldova V. Betisor and 
collaborators, then  Kirehead, Reddi, Jefferson, etc., have 
enriched the clinical studies in this domain. In “Colentina” 
Clinical Hospital from Bucharest we are concerned to 
improve the application in clinical activity and to research 
other STEM cells sources, as well as bone progenitor 
preparations (from 1978), having a significant number of 
cases and a wide range of applications currently available. 
The last years before the interesting discoveries and 
the role of some growth factors, not far behind in a time 
only “guessed” as having osteoprogenitor activity, the 
following have been clarified: 
-  TGF (Wrist); 
-  BMP (Beck); 
-  STEM replication factors; 
-  ,,Selectioned” cell cultures (Roberts); 
-  Obtaining and maintaining some 
mesenchymal cell lines with high 
osteoprogenitor potential (C3H1OT1/2 – 
Weber) in laboratory conditions. 
Cell cultures 
In the laboratories of “Nicolae Simionescu” Institute 
of Biology and Cell Pathology  from Bucharest, which we 
collaborate in the field of basic and clinical research with, 
we managed to obtain proliferation, differentiation and 
,,characterisation” of the osteoblasts from mesenchymal 
cells isolated from human bone marrow, after a very 
sustained activity of medium cultures preparation and after 
obtaining the means to preserve the cultures. Therefore, 
today we are able to use these cultures in surgery practice 
(sustained by different organic or synthetic supports, with 
different structures). 
Materials and methods 
From the bone marrow samples of different human 
patients, harvested by puncture from the postero-superior 
iliac spine, nucleotic cells have been separated on a 
density gradient and they have been grown in DMEM 
0.45% with a supplement of 15% fetal cow serum (SFB) 
and 10 mg/l of ascorbic acid. The osteoprogenitor cells 
(CO) obtained, are characterized by “fibroblast like” 
morphology and a positive reaction to alkaline 
phosphatase. The following implant materials have been 
used: pancol (P), matrix MG (MG), spongious human 
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bone without cells and different hydroxyapatite (HA). The 
implant materials have been conditioned in the same 
environment. We have highlighted that the cells have 
populated these implants through different optical and 
electronic microscopy techniques. CO differentiation into 
osteoblasts has been tested by putting in evidence the 
specific markers as: osteonectin (Osn) and bone 
sialoprotein (BSP) through immunofluorescence 
techniques. Fig.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A number of enzymes (alkaline phosphatase, 
osteocalcin) highlighted in fibroblast cultures, along with 
qualitative determination of sialoproteins are the first signs 
of conversion towards osteoformative cells of the 
mesenchymal cells elements. 
Results: Studies of optical and fluorescence 
microscopy have shown the various degrees of cellular 
population on the implant materials and HA used. A better 
settlement has occurred on Pancol and between three-
dimensional tested matrices, the best populated has been 
the human spongious bone. In the HA case, the factor that 
has determined the adhesion and cell multiplication has 
been the crystalline structure of the used hydroxyapatite. 
The ultrastructural examination (electronic transmission 
microscopy) has tested the presence of a rough well 
developed endoplasmatic reticle (RER), a great number of 
free ribosoms and secondary lysosoms in the case of 
matrix integrated cells. The reaction to alkaline 
phosphatase has been followed to see if it remains 
positive to cells grown on the HA coated supports. The 
immunofluorescence techniques have demonstrated the 
presence of Osn and BSP in the cells grown for one week 
on HA matrices. 
 
Conclusions: In the case of implant materials, the 
best settlement is achieved on the depopulated human 
spongious bone. Even in the cases in which the re-
population of the implant matrices is reduced, no ultra-
structural changes of the cells were registered. On the 
tested HA matrices, the cultures show very few 
differences regarding the alkaline phosphatase quantity 
and the differentiation between osteoblasts is not realized 
in all cases. The implants populated with human CO are 
used as auto-transplants in Orthopedic and Trauma Clinic 
of “Colentina” Clinical Hospital. 
 
Technique and methods of using the preparations 
are varied and some authors searched for ways to 
standardize them. This thing is still impossible as long as 
the role of some factors in certain phases of the 
osteogenesis, is not yet clarified. 
This is the reason why we expose the 
methodology used by us, with personal contributions to 
the clinical practice. 
 
1.  The massive bone graft containing STEM 
cells is usually harvested from postero-superior 
iliac crest (SIPS); this can be autogenous (the 
best situation) or homologous (with 
recommended tests done). We are using this 
“on-lay” or “in-lay” in lax pseudarthrosis infected 
or not infected, in great lacks of bone substance 
(essential osteolysis, osteitis with great volume 
of sechestrum elimination, bone defects after 
complex trauma with bone substance losses). 
Dysplastic diseases of the long bones or the 
osteochondronecrosis (NACF, knee 
osteochondritis), as well as infected 
pseudarthrosis of the mandible are lesions that 
have this method as treatment indication. Fig.2 
Fig.1 Making evident the alkaline phosphatase in 
osteoprogenitor cell cultures from spongy bone explant  (,,N. 
Simionescu" Institute of Cellular Biology and Pathology). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Bone graft with bone marrow aspirate from SIPS 
(center) (microscopic appearance, x 40, Van Gieson).   
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The osteomuscular decortication in 
pseudarthrosis, is an excellent adjoin; besides 
its known qualities, it is also added the finding 
that this ,,guided comminutive fracture” 
contributes to the releasing of osteoprogenitor 
cytokines. In the cases of great lack of bone 
substance, we have used the combination of 
osteoprogenitor graft (SIPS, ribs) with great 
fragments of ,,depopulated” and despecified 
bone. This has been realized by conservation to 
-4°C, in a sterile solution (culture medium for 
vegetal cells) type B5 (Gramberg), rich in 
mineral salts and some organic substances 
(zaharose, vitamin B) and a constant Ph (6.83-
6.85) for a very long time (6-8 months). 
Only the bone matrix of these grafts is kept 
strong, solid and well mineralised and the cells 
of any type, yellow marrow and soluble proteins 
disappear. Implanted at the pseudarthrosis site, 
very well prepared before and adding alive 
preparations of STEM type (grafts, macerate, 
and suspensions), the reconstruction is fast and 
firmly. The graft's re-population is done in a 
short time and on the old architectonic 
structures or other new ones, depending on the 
mechanical line forces. 
For the NACF, after practicing a trochantero-
capital tunnel of about 4-8 mm diameter (hand 
drilling) under Rx-TV control, the STEM 
preparation is inserted with the help of a 
calibrated trocar. The STEM preparation has a 
form of ,,carota of drill”, harvested from SIPS, 
without doing the curettage of the NACF site 
(we are also repeating an earlier finding: NACF 
does not mean necrobiosis but coexistence of 
an anarchic destruction-reconstruction process, 
due to localized vascular and mechanical 
disorders; besides, this drilling process that 
generates the release of local cytokines, that 
induce (through a similar mechanism to that 
exerted by interleukin-6) the bone 
reconstruction processes through the game of 
,,reciprocal induction” between osteoblast and 
osteoclast. 
2.  STEM preparations. They consist of selected 
soak spongious bone (SIPS, ribs) or soak 
STEM bone mixed with SIPS aspiration 
product, resulting in a kind of paste easy to be 
injected with the help of the trocar or easy to be 
modeled in a cavity zone. We are not 
recommending heparin to be added for 
stopping blood clot formation, just because the 
simple agitation of the preparation before being 
injected is enough to make it fluid, the blood 
clot being important through the 
osteoprogenitor factors released in the moment 
of the clot lysis. These osteoprogenitor factors 
together with graft medullocytes have an 
important role in osteogenesis (tixotropy). (Fig.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. Fig.3 a. Autotransplant, without instillation of osteoprogenitor 
preparation in the site, 10 days after the implantation (dog 
experiment, tetracycline fluorescence x 100). 
      b. Similar case which was added preparation. Note the 
intense activity of cellular repopulation. 
 
3. Mix implants (fresh graft from SIPS + 
depopulated graft + STEM type soak). They are 
used in great lacks of bone substance 
(pseudarthrosis and essential osteolysis or 
pseudarthrosis of the long bones appeared post-
trauma, elongations of the long bones that have 
a small osteogenic potential – humerus, tibia, 
etc.)  
4. SIPS osteocartilaginous graft. Harvested from 
child or adolescent it is used in NACF or knee 
osteochondritis. For this aim, it is shaped in a 
“carote” form, from SIPS, to size lesion, 15-20 
mm long (to reach the vascular region) and the 
spongious bone adjacent to the articular cartilage 
is removed. Thus, the graft is implanted with the 
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examinations and analysis required as homologous 
grafts (HIV, AgB, C etc.). We found that these 
exostosis, especially in some phases of growth, are 
extremely rich in medullocytes and in the regions 
(laminaes) of the new young bone, they are 
organized in Haversian lamelar systems, very well 
evidenced by PAS staining. (Fig. 4,5,6) 
cartilage toward articular cavity (on the trocar) for 
femoral head or through arthrotomy for the knee. 
5. A personal procedure. Spongious bone implant 
fragmented or soak from the osteogenic 
exostosis of children or adolescents have been 
used with excellent results. Of course, these 
exostosis have undergone anatomo-pathological  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5 a. Infected pseudarthrosis (osteitis) of the humerus. 
b. 3 months after local treatment (instillations of osteoprogenitor preparation) at every 21 days 
 
Fig.4 a. Secondary pseudarthrosis after osteitis of the femur, with large loss of bone capital - mixed fixing after the drain of the 
site. b. 60 days after grafting and instillation (every 14 days) of osteoprogenitor preparation. 
c. The same case, 5 months later. 
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Fig.6 a. Pseudarthrosis of the clavicle. b. The same treatment as in Fig. 5, 60 days later. 
 
Casuistic: Our experience spans the period 
1978-2008 and compiles: 
1. Pseudarthrosis (52 cases): 
-  clavicle (infected and non-infected); 
-  femur; 
-  tibia; 
-  humerus; 
-  intertrohanterian varisation osteotomy sites. 
2. Avascular Femoral Head Necrosis (48 cases): 
-  idiopathic; 
-  secondary. 
3.  Osteoarthritis (knee osteoarthritis, hip 
osteoarthritis) (89 cases). 
4. Post-traumatic osteolysis (5 cases): 
-  clavicle; 
-  femur; 
-  humerus. 
5. Essential osteolysis (idiopathic) (2 cases). 
6. Disecant knee osteocondritis (3 cases): 
-  medial femoral condyle. 
7. Limb elongations (6 cases): 
-  femur; 
-  shank; 
-  humerus. 
8. ,,Stress” osteoporosis (11 cases). This entity 
has been individualized and studied by us, especially in 
the last 14 years. There are local osteoporosis 
(postoperative, generally), regional, painful, embarrassing, 
that determine a hard mobilization of the patient. Our 
cases treated through STEM type grafts into the greater 
trochanter region or into the proximal methaphysis of the 
femur are: 
-  intertrohanterian osteotomies;  
-  cervico-cefalic prosthesis; 
-  total hip cemented prosthesis; 
-  humeral trohiter in a case of very painful 
PSH. 
9. Secondary osteoporosis. 
In the case of pseudarthrosis (1), our surgical 
treatment method can be outlined as it follows: 
-  drills and minimal guided fracturing in the 
pathological bone; 
-  instillation with a special syringe of a mixture 
containing factors with osteogenetic 
stimulative action, clinically and 
experimentally confirmed by our researches. 
Our personal casuistic is made up of a number of 
80-knee osteoarthritis operated by other surgical 
procedures than the total arthroplasty, followed up 
between 2 and 10 years. General conclusions are 
especially discussed in light of the results of some non-
invasive procedures used by us. After that, we have 
observed encouraging favorable follow-up for long periods 
of time (subcortical spongioclazia, trophic drills etc.). 
Starting from these observations (into the cases of painful 
knee osteoarthritis) we have extended the methods to hip 
osteoarthritis and finally, we have presented some 
conclusions that are recommending the use of this 
procedure (spongioclazia). 
There were also situations when major surgery 
(total prosthesis, the osteotomy) could not be practiced, 
the patient requesting the improvement of his condition 
(pain, the decrease in the movement’s amplitude, 
difficulties in walking). In these cases we have practiced a 
less invasive procedure (spongioclasia), presented below. 
The main indications for this type of surgery are: 
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-  Different associated diagnosed diseases that 
established a contraindication for a major 
surgery. 
-  Obesity, that patients could not or did not 
want to treat. 
 
-  The patients’ refusal to undergo a major 
surgery with a long period of recovery, from 
different reasons (fear, the lack of an 
assisting person, the impossibility to interrupt 
professional duties, etc.). 
-  The possibility to recover very quickly and be 
back to the quotidian activities and the 
advantage of having the recovery treatment 
in ambulatory conditions. (Fig. 7,8,9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 a. Open fracture, with large loss of bone substance (shank) 
b. The same case 6 months later (autografts with homolateral fibula and instillations at every 21 days). 
Fig.8 a. Resection of the medial condyle of the femur for giant cell tumor - osteoplastia with iliac bone and patella. 
b. Reconstruction and perfect reintegration 4 months later, during this time are made instillations every at 30 days. 
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Fig.9 a. Idiopathic knee arthrosis. 
b. Same case, 3 months after spongioclasia and instillation. 
The surgical technique to the knee level is 
relatively simple. After marking the important anatomical 
reference points (tibial tuberosity, femuro-tibial 
interarticular line, the head and the apex of the fibula, the 
anterior crest of the tibia and the postero-medial edge of 
the tibia) on the skin, an oblique line will be drawn 
beginning from the postero-medial edge of the tibia  
 
(corresponding to tibial tuberosity as a landmark) which 
passes in the immediate proximity of tibial tuberosity and 
ends at the fibular apex. Through a vertical incision of 0.5–
2cm (in the case we are also introducing a bone graft) or 
through a simple hole prevailing on the medial region of 
the shaft on this line, the tibia is approached at 15-20 mm 
distance ventral of the postero-medial edge. (Fig.10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig.10 Syringe for instillation. 
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A hole in the cortical is done with a manual drill 
(crank, chisel of 8 mm) and a blunt instrument is 
introduced (spongiotom) by sectioning the spongious bone 
in a circular manner, always following the internal contour 
of the cortical bone. This way we obtain a subcortical 
,,osteotomy” of the spongious epiphyso-metaphysial 
structure (subcortical spongioclasia). In addition, we 
partially obtain a combination of the osteotomy and the 
drill effects. In cases of more advanced osteoarthritis (std. 
II, III and even IV) where the subchondral osteonecrotic  
 
lesions at the medial condyle level are constant, we 
introduce a cortical graft (autologous or homologous) 3-
5cm long, placed transversely, so that anterior and 
posterior communication exists, with the cavity created 
during spongioclasia, for the venous drainage. The trophic 
and bone regenerative effect of this graft, observed much 
earlier and subsequently confirmed is also completed by 
our observation that its integration as well as the 
remodeling of the bone are ,,sustaining” elements of the 
tibial condyle. Therefore, the deformation and tibial 
varisation are stopped or even reduced. (Fig. 11-13)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
Fig.11 Angiography of 
the proximal extremity of 
the tibia. Note the 
diaphyseal arterial 
circulation proceeded 
from the nutritional artery, 
and the epiphyseal one 
from periostic and 
capsulo-ligament 
sources. 
 
Fig.12 The two territories with 
nutritive irrigation are separated at the 
level of former growth cartilage. 
 
 
 
 
 
 
Fig.13 After spongioclasia (3 
months) an improvement of 
the arterial epiphyseal 
irrigation (experimental, dog 
tibia) is noted. 
During the last 5 years, we have stopped performing 
bone graft procedures while we continued performing only 
spongioclasia. 
We have instilled an autologous preparation (STEM 
osteoprogenitor) in the site of the spongioclasia, whose 
short-term (2 years) effects are more than encouraging. 
In the last 4 years, we have added the perforation of 
4 channels in the metaphysial plaque (the old growing 
cartilage) to assure a circulatory diaphysial medulo-
endostic flux towards epiphysis, which, in the case of the 
tibia, is predominantly of a periostic or capsulo-ligamentar 
origin. 
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After the operation, walking debuts in 24 hours 
using cane or crutches (50% load for 14-21 days), 
continuing with the progressive resumption of full support 
in 35 days. From the 21st day, the patient can begin 
physiotherapy (profound diathermy, ultrasounds) and 
muscular massage. This recovery treatment is repeated 2-
3 times per year, for up to 3 years. 
Sex distribution of patients point out that women 
have registered higher scores (postoperatively) than men 
(the same procedure to the hip level seems to give better 
results in men). 
From the age point of view, the best results have 
been encountered in the 50-65 year old segment of age, 
poorer results over 65 y.o. and partially good (especially in 
pain improvement) in the 35-60 years range. In some 
patients with painful sechelae we have associated 
articulary denervation (4 cases) followed by a durable 
improvement. 
All the cases that have been treated through 
spongioclasia have benefited from physio-kineto-
balneotherapy, that undoubtedly contributed to the quality 
of results. (Fig.14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: 
-  this surgical procedure is minimally invasive and 
very easily performed. 
-  surgical procedure “of waiting”, (very often with 
definitive character or for a long period of time) 
if the patients follow the postoperative treatment 
very accurate; 
-  Regional trophic circulation is improved, with 
remarkable results regarding pain and the 
functionality of the knee, probable due to: 
•  use of autografts and homografts, biological or 
synthetic matrices, treated with osteoprogenitor 
factors associated with osteoblasts cultures; 
•  bone remodeling stimulation; 
•  a new architecture of the spongious bone (similar 
to a normal one); 
•  intra-osseous denervation obtained through spongious 
bone trituration, with antialgic effect. (Fig. 15-17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 NACF, before (a) and after (b) instillation of 
osteoprogenitor preparation by trochantero-cervico-capital 
drilling (result after 3 months). 
 
Fig.14 MRI before (a) and after (b) spongioclasia and 
instillation of preparation (hip arthrosis) at every 3 months.  
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,,Stress” osteoporosis segmental (8) has been 
recently individualized. In 1994, Gallant, Fisher, Sziklas 
(Connecticut) have been between the first clinicians who 
have signaled the post-traumatic regional, post-operative 
and post-inflammatory osteoporosis (foot, ankle), with a 
very close simptomatology to that of algic osteoporosis 
(Leriche). However, the segmental osteoporosis (of a 
restrained circumscribed zone) that appears isolated at 
the great trochanter level, acromion, clavicle extremities, 
distal epiphisis of radius and ulna, lunatum, trohiter, has 
not been studied or specially evidenced. 
Segmental osteoporosis is also mentioned at a 
vertebra level (Garland, Foulkes, Adkins, Stewart, Yakura 
-1994) at variable intervals after trauma. Simptomatology 
and the disease follow–up have identified almost entirely, 
what we knew as Kummel-Verneuil syndrome (studies 1 
and 2). 
Several years after the beginning of mainstream 
metal or ceramic implants (hemiartroplasties, artroplasties 
or artro-osteoplasties in different diseases - arthrosis, 
rheumatisms, tumors) an increased number of loco-
regional segmental osteoporosis or generalized 
osteoporosis has been observed. 
Regional segmental osteoporosis (causalgia, 
Sudeck osteodistrophy, postraumatic osteoporosis, 
algodistrophy, shoulder-hand syndrome) has various 
causes: 
-  Post-traumatic. 
-  Post-operative. 
-  Post-insertion of an implant: 
•  polyethylene; 
•  cement; 
•  metallic fragments; 
•  mechanical stress; 
•  bone nerve destruction; 
•  bone vascular destruction. (Fig. 18) 
Fig.16 Similar case, the same treatment. Initial appearance 
(a) and 3 months later (b). 
Fig.17 Idiopatic gonarthrosis immediately after 
spongioclasia and stem instillation (a) and 3 month later (b). 
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Installation mechanisms can be ordered: 
-  Chemical (polyethylene, carbon). 
-  Local biological (cement fragmentation or 
detachment of small metallic particles from 
prosthesis). 
-  Local congestion determined by the “foreign 
body” existence. 
-  Local elasticity “incompetence”. 
-  High initial temperature of the cement (80 
degrees). 
-  Tissular destructions consecutive to local 
drills. 
-  New mechanical stress, non-physiological 
(local) due to changes of original movement 
axes. 
-  Type of the prosthesis sterilization (best way 
with Gamma radiation).  
 
In the case of older people, the osteoporosis 
manifestations appear earlier and intensely because of the 
osteoclasts and macrophages predilection to activate 
themselves at minimal stimuli (Kevin D.Freston), but 
clinically and radiologically, a healthy bone does not 
appear with big differences in comparison with an 
operated one, as it was observed in younger patients. 
Osteodensiometry is the investigation that establishes the 
positive diagnosis. 
  The installation mechanism of this osteoporosis of 
“prosthesis” could consist of a stimulation of the unspecific 
activity of the white blood series, the activity of the 
osteoclasts being concomitant, but secondary as 
importance (Howie, Maloney, 1989; Parr, 1995; Lauzer 
etc.). 
  This opinion can be sustained by anatomo-
pathological observations that are showing, on samples 
taken from the region, granulomatous lesions with giant 
cells, histiocytes with phagocytic properties, along with 
metallic debris, polyethylene debris, ceramic or poliacrylic 
cement debris. 
  We cannot still say for sure which type of total 
prosthesis (hip or knee) cemented or non-cemented, leads 
to the appearance of local segmental osteoporosis in a 
greater percent. Regarding the non-cemented prosthesis, 
Charnley was the first to signal osteoporosis that is still 
present even 10-15 years after the operation. The same 
thing is signaled even since the 1970s by Maloney. The 
incrimination of the cement is also sustained by Harris, 
Santavirsta etc. Whichever the cause, osteoporosis of this 
type is extremely refractory to the treatment. 
  Decades ago, Urist was defining osteoporosis as 
“the most common bone dismetabolic disease”. The 
modern reality lays this disease close to obesity and 
diabetes mellitus as the top metabolic diseases, but it is 
distinguished by the fact that the endocrine and nutritional 
elements incriminated in its own etiopathogeny cannot be 
objectively quantified. 
Fig.18 Regional osteoporosis (after bilateral PTS), 
acetabular and trochanterian. 
  Being a chronic disease that interests the skeleton 
totally or partially, transitory or chronically, the 
osteoporosis is characterized by anomalies to microscopic 
and macroscopic level of the bone tissue (having as main 
characteristic the bone mass reduction as a result of 
specific matrix alteration) on unit volume of this mass. The 
consequence of this trophic-metabolic deficit is bone 
fragility, which can determine the increase of the risk of 
fractures, para-articular deformities (by trabecular micro-
fractures into the spongious epiphysial bone) and often 
very serious functional perturbations. 
 
Secondary osteoporosis (9) has as main causes 
the following: 
-  Systemic immunological diseases (rheumatoid 
arthritis). 
-  Osteoporosis caused by effort: young athletes 
(calcaneum, cuboid, navicular bone). 
-  Professional osteoporosis – X-radiation 
exposure, high temperatures in steel works, 
variations of gravity (astronauts), vibrations 
exposure, prolonged intellectual stress 
-  Osteoporosis caused by chemical-biological 
factors - Pb, Si, Sr, Cd, Hg, cyclic carbohydrate, 
oligosymptomatic chronic infections. 
-  Osteoporosis caused by medicines – cortisone, 
AINS, diuretics, immuno-suppressive medicines. 
This entity is more frequent than we are tempted 
to believe. 
The treatment proposed by us consists into the 
following surgical procedure: 
-  Bone aspirate from SIPS that is containing 
STEM cells (mesenchymal cells). 
-  Dexamethasone. 
-  Manual lysis of the sanguine clot to release 
PDGF from platelets (tixotropy). 
-  Active forms of Vitamin D3. 
This combination is injected in the osteoporosis site 
and has as result the diminishing of pain. The patient 
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remains to be followed up and is associated, where 
appropriate, physiotherapy and kinetotherapy. 
Good results obtained in these cases (as well as in 
the patients included in paragraphs 1, 4 and 5) could have 
possible explanations like: 
-  Sanguine clot lysis → release of PDGF. 
-  Dexamethasone  → initiates STEM cells 
transformation. 
-  Proliferative response to PDGF action, which is 
observed in several types of mesenchymal cells 
(STEM cells). 
-  TGFβ derived, probably from active TH1 cells (T-
helper) and from natural-killer (NK) cells and 
those exert anti-inflammatory effects (suppresses 
cytokine production), stimulates healing, inhibits 
macrophages and lymphocytes proliferation. 
 
Conclusions: 
Discussing the results while taking into 
consideration an objective ,,score” is not possible. The 
cases, even though various, evolving almost identically 
(as stages), except for some diseases (limb elongations, 
infected pseudarthrosis, secondary and essential 
osteolysis) required prolonged time to be solved. 
Clinical and laboratory means for patient evaluation 
are revealing, but for interpreting the therapy results with 
these factors, we recommend assessment methods such 
as: 
-  Clinical evaluation: 
•  pain; 
•  mobility; 
 
•  different scores; 
•  subjective element : patient satisfaction. 
-  Paraclinical tests: 
•  X-rays; 
•  MRI; 
•  CT; 
•  scintigraphy. 
-  Laboratory tests: 
•  complete microscopical tests. 
  Finally, we resume the benefits of 
osteostimulative progenitor factor therapy: 
-  It is a modern therapy, for the future. 
-  It is relatively easy to apply and is not requiring 
very complicated instruments. 
-  It is a dynamic method, with action in time, at 
distance from the moment of surgery. 
-  It is a biological surgical method belonging to the 
so-called “ecological surgery”. 
-  It has a wide range of indications and the 
preparations are relatively easy to obtain. 
-  Clinical experience of many practitioners qualifies 
it as an exceptional therapeutic method. 
-  Giving the large applicability sphere (over 55% of 
the casuistic), we consider that intensifying 
research especially interesting osteoblasts cells 
cultures will be particularly benefic in solving an 
extended range of problems of locomotory 
apparatus pathologies. 
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